This site is intended for health professionals only
Newsletter
Hospital Healthcare Europe
Login
Twitter
Linkedin
Facebook
Select Language
English
French
German
Italian
Spanish
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Events
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Events
Home
>
Central nervous system
Central nervous system
Novartis supplies MenB vaccine, Bexsero®, to protect Princeton students
Generics and HIV: cost versus care
Tivicay® for treatment of HIV receives positive CHMP opinion
Teriflunomide: a new choice in the oral MS drug market?
Novartis’ Gilenya® long-term efficacy on reducing brain volume loss and real-world relapse rates in MS
Lemtrada approved in EU for MS
FDA expands age indication for Menveo®
JCVI not to recommend Bexsero®
HIV mortality rates identical
Switching to Novartis drug Gilenya
New data shows Gilenya benefited multiple sclerosis
World MS Day
« Previous
1
…
3
4
5
6
7
…
28
Next »
Most read
1
Transcranial magnetic stimulation brain connectivity changes in major depression visible on MRI scan
by Rod Tucker
2
Oral vitamin A could become an alternative to isotretinoin for acne
by Rod Tucker
3
Amino acids supplement reduces muscle wasting and improves gut function in critically ill
by Rod Tucker
4
Less than two-thirds of patients alive 10 years after out-of-hospital cardiac arrest
by Rod Tucker
5
Launch of the new Hospital Pharmacy Europe Mobile App
by aporter2
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
x
Search for: